Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry

BACKGROUND: The use of imatinib, sunitinib, and regorafenib has transformed the treatment of advanced GIST. Sunitinib and regorafenib improve progression free-survival in the second (2L) and third (3L) line, respectively, compared with placebo. However, the impact of these agents on overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Call, Jerry W., Wang, Yu, Montoya, Denisse, Scherzer, Norman J., Heinrich, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446260/
https://www.ncbi.nlm.nih.gov/pubmed/30984366
http://dx.doi.org/10.1186/s13569-019-0114-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446260/
https://www.ncbi.nlm.nih.gov/pubmed/30984366
http://dx.doi.org/10.1186/s13569-019-0114-5

Ejemplares similares